Biomedica and Cancer Research
18 March, 2019
Biomedica features new biomarkers for cancer research at ISOBM 2018
Biomarkers have the potential to improve clinical results in cancer prevention, diagnosis and therapy. At the ISOBM Congress, relevant new findings in research, diagnosis and clinical oncology will be discussed with the goal to ultimately improve patient’s state and survival.
Visit Biomedica’s team at the posters and learn more about the recently released ELISA assays for total soluble Neuropilin-1 and soluble Semaphorin 4D for cancer research:
- Development of a Sandwich ELISA for Total Soluble Neuropilin-1 – A Decoy Receptor for VEGF
- Quantification of Pro-angiogenic, Soluble Human Semaphorin 4D by Sandwich ELISA
Click on the products for detailed product information on: